Prevalence of Baseline Polymorphisms for Potential Resistance to NS5A Inhibitors in Drug-Naive Individuals Infected with Hepatitis C Genotypes 1–4
暂无分享,去创建一个
[1] Min Gao,et al. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. , 2013, Current opinion in virology.
[2] J. Pawlotsky. NS5A inhibitors in the treatment of hepatitis C. , 2013, Journal of hepatology.
[3] F. Mcphee,et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[4] I. Água-Doce,et al. Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay , 2013, Journal of medical virology.
[5] Kenji Ikeda,et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. , 2013, Journal of hepatology.
[6] P. Targett-Adams,et al. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. , 2012, Virus research.
[7] Lingling Jia,et al. In Vitro Activity of Daclatasvir on Hepatitis C Virus Genotype 3 NS5A , 2012, Antimicrobial Agents and Chemotherapy.
[8] Yoshiyuki Suzuki,et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[9] H. Mo,et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. , 2012, Journal of hepatology.
[10] E. Poveda,et al. Prevalence of Natural Polymorphisms at the HCV Ns5A Gene Associated with Resistance to Daclatasvir, An Ns5A Inhibitor , 2012, Antiviral therapy.
[11] R. Nettles,et al. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS‐790052 , 2012, Hepatology.
[12] Anna Persson,et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. , 2012, The New England journal of medicine.
[13] Lingling Jia,et al. In Vitro Activity of BMS-790052 on Hepatitis C Virus Genotype 4 NS5A , 2011, Antimicrobial Agents and Chemotherapy.
[14] Xin Huang,et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations , 2011, Hepatology.
[15] Min Gao,et al. Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System , 2010, Antimicrobial Agents and Chemotherapy.
[16] Min Gao,et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect , 2010, Nature.